The goal of this study is to assess response to kisspeptin as well as the baseline patterns of luteinizing hormone (LH) secretion in individuals with polycystic ovarian syndrome (PCOS).

Assignment: All study subjects will undergo the same interventions. Baseline LH secretion patterns of individuals with PCOS will be compared to their LH secretion patterns while receiving a kisspeptin infusion.

Delivery of Interventions:

• Prior to the inpatient study visit, the subjects will undergo a review of their medical history, physical exam, and screening laboratories.

• On the day of the study, the subjects will have an intravenous (IV) line placed and

  • Undergo up to q10 min blood sampling x 36 hours
  • Receive an infusion of kisspeptin x 24 hours
  • Receive up to two kisspeptin IV boluses

• Ages 18-45 years

• A history of clinical diagnosis of PCOS or equivalent clinical features

• BMI >18.5 and <35 kg/m2

• Normal blood pressure (systolic BP < 140 mm Hg, diastolic > 90 mm Hg)

• Laboratory studies:

  • Negative human chorionic gonadotropin (hCG) pregnancy test prior to kisspeptin administration
  • Hemoglobin no less than 0.5 g/dL below the lower limit of the reference range for healthy women

• Not using hormonal medication or willing to complete an appropriate washout for that particular medication and its method of administration

• No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and its method of administration

• No excessive alcohol consumption (>10 drinks/week) and/or ongoing use of illicit drugs

  • Any current use of marijuana will be evaluated by a study medical professional to determine if it is expected to impact study participation

• Not pregnant or trying to become pregnant

• Not breastfeeding

• No history of bilateral oophorectomy (both ovaries removed)